Figure 1

Susumu Fukahori

and 8 more

Rationale, aims and objectives; For asthma strategy, to avoid the aggravation of bronchial inflammation and contraction, the addition of long acting beta agonist (LABA) to inhaled corticosteroids (ICS) has been recommended. To know whether there is any clinical difference between the additional efficacies of formoterol (FOR) and tulobuterol (TUL) onto budesonide (BUD) may be useful for the elderly patients’ asthma treatment strategy. Method: Eighteen outpatients with mild to moderate bronchial asthma with FEV1.0% < 80% treated by intermediate ICS dosages visited Respiratory Division of Nagasaki University Hospital or Isahaya General Hospital, Japan Community Health care Organization were subjected. Subjects were randomly assigned (9 cases per group) to either the FBC group (BUD/FOR 160/4.5 mcg: 2 inhalations twice daily) or BUD + TUL group (BUD 200 mcg: 2 inhalations twice daily + TUL 2mg daily) and were compared in parallel with 2 arms for 12 weeks prospectively. PEF, FEV1, impulse oscillometry (IOS), fractional exhaled nitric oxide, Asthma Control Questionnaire and mini-Asthma Quality of Life Questionnaire (mini-AQLQ), and occurrence of adverse reactions were compared. Results; The “Fres” of IOS was improved (p=0.03) in FBC group. The “emotion” domain of mini-AQLQ was improved (p=0.03) in BUD+TUL group. Conclusions; By changing the drug formulation, the patch was superior in terms of satisfaction, but it was thought that the inhaled combination was superior in improving the respiratory function itself. It is necessary to pay attention to the characteristics of the patient when selecting treatment.